Apr 20, 2026, 8:30 AMaccessnewswire.comBMNDF
Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States
Company announcements
A defining moment for the future of mental health, and for Biomind's mission to transform neuropsychiatric care through next-generation psychedelic medicines TORONTO, ON / ACCESS Newswire / April 20, 2026 / Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a clinical-stage bio-pharmaceutical company focused on transforming breakthroughs in neuroscience and biomedical research into novel pharmaceutical drugs, today welcomes the historic executive order signed by President Trump to accelerate research, regulatory pathways, and patient access to psychedelic treatments. This landmark policy shift marks a turning point in U.S. healthcare and drug policy, one that aligns directly with Biomind's long-term vision: to redefine how the world treats mental health and brain-related conditions.
